November 21, 2008
| Bio-IT World > Rubin's Risky Business
Rubin's Risky Business


Oct. 16, 2006 | Gerry Rubin's successful partnership with Craig Venter to sequence the Drosophila genome in 1999 was a stunning dress rehearsal for Celera's assembly of the human genome. But for Rubin, it was an end in itself, the culmination of the UC Berkeley geneticist's decade-long dream to sequence the genome of his favorite model fruit fly.

In 2000, seeking a fresh challenge, Rubin joined Nobel laureate Tom Cech as the new leadership team at HHMI, ushering in a new era of "risky" research and encouraging - nee insisting that - the nation's smartest scientists use the institute's lavish resources to conduct bolder, more imaginative lines of research.

But Janelia Farm represents an even bolder vision - a new interdisciplinary research campus modeled on Bell Labs to foster new technologies and areas of research. "We started with the premise that we'd try to do things that aren't done well elsewhere," a relaxed Rubin told me. "There's not been good funding for developing new tools and new methods."

Rubin wanted to avoid high-profile areas such as genomic medicine, where "smart people will get money from the NIH." Instead, HHMI looked for problems that would benefit from an interdisciplinary environment, ideally with a technological component. Following a set of scientific workshops, two major goals/criteria were identified.

Says Rubin: "One was the goal of understanding how information is stored and interpreted in the nervous system. It starts with the premise - which I hold strongly - of evolutionary conservation. We believe that there are fundamental mechanisms underlying how information is processed in all animals and we can discover these mechanisms in genetically tractable organisms, such as fruit flies, mice, worms."

Rubin commends the NIH for pouring money into research on Alzheimer's, Parkinson's, and other neurological disorders, but there is little left for basic research. "This may be medically relevant in 30-40 years," says Rubin. "That's fine, that's soon enough."

The other goal for Janelia Farm is to develop methods and techniques to image neural activity. "NIH spends lots of money on imaging, but its nearly all human diagnostics," Rubin explains. "We want to study the nervous system and improve imaging methods, build better microscopes, and [develop] computational analysis."

As for his own research, Rubin has scoped out his own project "to identify all the enhancers and promoters in the Drosophila genome that are directed to subsets of cells in the adult brain." The project involves making thousands of transgenic animals, using his extensive high-throughput genomics experience. The end result will be a valuable tool for the community.

Misfits and Molecules
What particularly pleases Rubin is the preponderance of physicists arriving at Janelia Farm. "We have more people with physics undergraduate degrees than biology degrees: We have mathematicians, computational scientists, physicists, biologists, they're all beginning to interact."

One of the early arrivers is Gene Myers, former chief of informatics at Celera. "The type of people working at Celera in its heyday are exactly the type of people we want working here," says Rubin. "We wanted to be different. We didn't want to be competitive with Harvard Medical School or the Whitehead Institute.... We wanted to do things here that attract "misfits" - people that don't fit into conventional academic institutions."

Breaking these boundaries is paramount for HHMI's bold experiment to succeed. The research facility contains 147,000 square feet of Belgian glass, one of the largest installations in the US, providing open visibility into every laboratory. Compressed lunch hours encourage communal dining; and there is a pub named "Bob's" after HHMI's resident architect, Bob McGee, which Rubin says serves a "nice cappuccino" and another communal venue in the evenings.

Janelia Farm has its skeptics, but that's fine with Rubin. "Half of people think this is just crazy. Only ten percent people say this is for them, this is where I want to be. My goal going in was for Janelia to be different enough that only ten percent of scientists would be enthusiastic." -- K.D.

Return to main article.

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

Waters white paper image
Software Helps Doping Control Lab Streamline Results Management
Sponsored by Waters
The Karolinska University Hospital’s Doping Control Lab tests thousands of samples annually for stimulants, diuretics, and other masking agents. Increased regulatory pressure and new technologies increased the number of samples analyzed creating data management challenges. Waters® NuGenesis® Scientific Data Management System and TargetLynx™ Application Manager software were used to reduce the time required to calculate, review and search results.


sas whitepaper92
Managed Innovation, Assured Compliance
Sponsored by SAS
Discovery organizations are identifying a lot of promising compounds, but clinical research processes haven't kept pace with timely testing of all those potential therapies. This white paper describes how SAS® Drug Development supports true innovation across the clinical trial process.

In this white paper you will learn how to:

  • Assemble data to foster better collaboration
  • Get up-to-date information during clinical trials
  • Make informed decisions earlier in the trial process


BlueArc white paper image
Addressing Life Sciences Constantly Growing Data Challenges Research Environments
Sponsored by BlueArc
The continued explosion of raw experimental data, the increased use of video, the growing adoption of new data retention practices, and the move to high throughput computational workflows are all placing new demands on the way life sciences organizations store and manage their data.

Download this white paper to learn about:

  • Factors driving the data explosion in the life sciences
  • New data management issues that must be addressed
  • HPC trends that are placing new demands on storage
  • Storage solution attributes that address performance, manageability, and energy efficiency.


Life Science Webcasts & Podcasts

Medidata Solutions

Rising Clinical Trial Delays and Costs - Addressing the Cause, Not the Symptoms 

medidata podcastProtocol complexity is taking a toll on clinical study speed and efficiency: increasingly complicated and ambitious protocols are not only burdening sites and study volunteers but are also prolonging trials and increasing expenses. In response, sponsors have turned to global study placement, restructured site relationships and new site management practices, but the problem remains.

This podcast will discuss:

  • Why these responses address only the symptoms, not the underlying cause, of rising clinical trial delays and costs.
  • Results of a recent joint Tufts University / Medidata Solutions study.
  • New metrics benchmarking protocol design trends.
  • Systematic protocol design improvements and why they are essential to clinical trial performance excellence.

Speakers: Ken Getz, Senior Research Fellow at the Tufts Center for the Study of Drug Development, and Ed Seguine, General Manager, Trial Planning Solutions at Medidata.

Download Now 



More Podcasts

Job Openings

Director, Center For Information Technology (CIT) - National Institutes of Health  (NIH), Department of Health and Human Service
Located in Bethesda, MD. This position requires:
• High-level vision, leadership, management, and modernization of CIT programs and services.
• Strategic direction and policy development for CIT long-term operations and objectives.
• Serve as a key IT advisor to the NIH Chief Information Officer.
A TOP SECRET security clearance will be required.  More job detail is found at:  http://www.jobs.nih.gov under the Executive Jobs section.Or contact Ms.Winnie Garner at seniorre@od.nih.gov.  Applications must be received ELECTRONICALLY by (11:59 p.m.), December 17, 2008.  DHHS and NIH are Equal Opportunity Employers

Bioinformatics Manager- Lilly Singapore Centre for Drug Discovery
For more information click here 

For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA;

(717) 399-1900 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.